Navigation Links
Lotus Pharmaceuticals Announces Key Changes
Date:1/15/2010

BEIJING, Jan. 15 /PRNewswire-Asia-FirstCall/ -- Lotus Pharmaceuticals, Inc. (OTC Bulletin Board: LTUS) ("Lotus" or the "Company"), a growing developer and producer of prescription drugs and licensed national seller of pharmaceutical products in the People's Republic of China ("PRC"), today reported that its newly engaged auditor is Friedman LLP and legal counsel McLaughlin & Stern LLP.

The Company was notified that the audit practice of Bagell, Josephs, Levine & Company, LLP, the Company's independent registered public accounting firm ("BJL"), joined with Friedman LLP ("Friedman") effective as of January 1, 2010. On January 12, 2010, BJL resigned as the independent registered public accounting firm of the Company and, with the approval of the Audit Committee of the Company's Board of Directors, Friedman was engaged as the Company's current independent registered public accounting firm.

BJL was engaged as the Company's independent accountants on April 24, 2009. From April 24, 2009 through January 12, 2010, there were no disagreements between the Company and BJL on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure, which disagreements, if not resolved to its satisfaction, would have caused BJL to make reference to the subject matter of such disagreements in connection with its report,

The Company has also engaged McLauglin & Stern, LLP. as its securities legal counsel.

CEO, Zhongyi Liu, said, "We are looking forward to working with our new auditor and legal counsel to add values for our shareholders."

About Friedman LLP

Friedman LLP, Accountants and Advisors, is headquartered in New York City with offices in New Jersey and Long Island. As of January 1, 2010, Friedman LLP has over 325 professionals and personnel, providing accounting, tax and consulting services to public and privately held companies. For further information, please visit http://www.friedmanllp.com .

About McLaughlin & Stern, LLP.

McLaughlin & Stern, LLP, established in 1898, is one of New York's oldest law firms. The firm provides a diverse range of sophisticated legal services to businesses and individuals, offering legal expertise in mergers and acquisitions, corporate finance, litigation, real estate, intellectual property, health care, family law, tax, environmental law, maritime law, art law, trusts and estates and other private client matters. It has 70 lawyers in New York City, Milbrook, New York and West Palm Beach, Florida. For more information, please visit http://www.mclaughlinstern.com .

About Lotus Pharmaceuticals, Inc. ( http://www.lotuspharma.com )

Lotus Pharmaceuticals, Inc. is a growing developer and producer of prescription drugs and a licensed national seller of pharmaceutical items in the People's Republic of China. Lotus operates through its two controlled entities: Liang Fang Pharmaceutical, Ltd. and En Ze Jia Shi Pharmaceutical, Ltd. Lotus' current drug development pipeline is focused on the treatment of cerebro-cardiovascular disease, asthma, and diabetes. Liang Fang sells drugs directly and indirectly through its national sales channels to hospitals, clinics and drugs stores in 30 provinces of the PRC.

    For more information, please contact:

    Lotus Pharmaceuticals, Inc.
     Yan ZENG, CFO
     Tel:   +86-10-6389-9868
     Email: zy@lotuspharma.com

SOURCE Lotus Pharmaceuticals, Inc.

RELATED LINKS
http://www.lotuspharma.com
http://www.friedmanllp.com
http://www.mclaughlinstern.com

'/>"/>

SOURCE Lotus Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine news :

1. Lotus Pharmaceuticals, Inc. Again Awarded GSP Certification
2. Lotus Pharmaceuticals, Inc. to Exhibit at the 2009 International Conference for Bioeconomy
3. Lotus Pharmaceuticals, Inc. Reports First Quarter 2009 Financial Results
4. Lotus Pharmaceuticals, Inc. Reports Strong 2008 Financial Results
5. iEnterprises Launches iComply, Lotus Notes Email Archiving and Compliance Software
6. Lotus Pharmaceuticals, Inc. Purchases Intellectual Property Rights to an Established Prescription Drug
7. Lotus Pharmaceuticals, Inc. Purchases Land Use Rights to Grow its Business and Reduce Costs
8. Lotus Pharmaceuticals to Present at Rodman & Renshaw Conference
9. Lotus Pharmaceuticals Announces Conference Call to Discuss Second Quarter 2008 Results
10. Lotus Pharmaceuticals, Inc. Reaffirms its Confidence in Meeting its Make Good Target for Fiscal Year 2008
11. Lotus Pharmaceuticals, Inc. Announces Conference Call to Discuss First Quarter 2008 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2017)... (PRWEB) , ... April 28, 2017 , ... Horizon Blue ... affirmed the company’s credit rating of “A” and its outlook as “stable.” At the ... capital reserves, which have fallen in recent years, dip below “capital adequacy” thresholds required ...
(Date:4/28/2017)... ... April 28, 2017 , ... Ushio America proudly introduces ... an instant energy-saving solution for F32T8 fluorescent lamps on most instant-start and programmed-start ... 50,000 hour rated lamps utilize the existing electronic ballast, saving labor and maintenance ...
(Date:4/28/2017)... ... ... The Texas Cord Blood Bank (TCBB), a program of nonprofit biomedical organization ... Hospital at Renaissance in Edinburg for their outstanding efforts in collecting umbilical cord blood ... , “Women’s Hospital at Renaissance has been a collection partner for the TCBB ...
(Date:4/28/2017)... (PRWEB) , ... April 28, 2017 , ... Bill Howe ... industry in the coastal communities. After Tina Howe joined the team, the Bill Howe ... employees, honest services at affordable rates, and giving back to the San Diego community ...
(Date:4/28/2017)... , ... April 28, 2017 , ... ... work assisting the Brooke Grove Foundation implement a Microsoft Dynamics GP solution that ... a leading ERP expert that specializes in long-term care, Brooke Grove now has ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... April 19, 2017 The Global Effective ... to 2022 report has covered and analysed the potential of ... on market size, shares and growth factors. The report identifies ... and opportunities in the global market. ... Browse 152 Tables and Figures, 6 Major Company ...
(Date:4/19/2017)... , April 19, 2017 ... stimulate an immune response in pets such as ... products are of various types such as Attenuated ... Toxoid Vaccines, DNA Vaccines and Recombinant Vaccines. Attenuated ... as virus or bacteria, which have been weakend ...
(Date:4/19/2017)... 2017  Novartis today announced the publication of ... and Blood Institute (NHLBI) of the National Institutes ... with treatment-naïve severe aplastic anemia (SAA) achieved complete ... at the initiation of and concurrently with standard ... sequential treatment groups, or cohorts. Cohort 3 added ...
Breaking Medicine Technology: